The next step in homogenous bioconjugate development: Optimizing payload placement and conjugate composition

BioProcess International

Volumn 12, Issue , 2014, Pages

  Bhat, Abhijit S ^a   Rabuka, David ^a   Bleck, Gregory ^b  

^a Redwood Bioscience Inc   (United States)

^b CATALENT PHARMA SOLUTIONS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE; CYSTEINE; LYSINE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE;

ARTICLE; CONJUGATE; DISULFIDE BOND; GENE EXPRESSION SYSTEM; HEAVY CHAIN; LIGHT CHAIN; NUCLEOPHILICITY; PROTEIN ENGINEERING; STOICHIOMETRY;

EID: 84910626759     PISSN: 15426319     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (27)

1. Biotech Products in Big Pharma Clinical Pipelines Have Grown Dramatically. Tufts CSDD Impact Report 15(6) 2013.
2. PhRMA 2013 Report. Overview, Medicines in Development: Biologics. Pharmaceutical Research and Manufacturers Assocation: Washington, DC, 2013; www.phrma.org/sites/default/files/pdf/biologics2013.pdf.
3. Finco O, Rappuoli R. Designing Vaccines for the Twenty-First Century Society. Front. Immunol. 5(12) 2014: 1-6.
4. Veronese FM, Mero A. The Impact of PEGylation on Biological Therapies. Biodrugs 22(5) 2008: 315-329.
5. Sievers EL, Senter PD. Antibody-Drug Conjugates in Cancer Therapy. Annu. Rev. Med. 64, 2013: 15-29.
6. Zolot RS, Basu S, Million RP. Antibody-Drug Conjugates. Nat. Rev. Drug Disc. 12(4) 2013: 259-260.
7. Wang L, et al. Structural Characterization of the Maytansinoid-Monoclonal Antibody Immunoconjugate, huN901-DM1, By Mass Spectrometry. Protein Sci. 14(9) 2005: 2436-2446.
8. Doronina SO, et al. Development of Potent Monoclonal Antibody Auristatin Conjugates for Cancer Therapy. Nat. Biotechnol. 21(7) 2003: 778-784.
9. Sun MMC, et al. Reduction-Alkylation Strategies for the Modification of Specific Monoclonal Antibody Disulfides. Bioconjuate Chem. 16(5) 2005: 1282-1290.
10. Senter PD, Sievers EL. The Discovery and Development of Brentuximab Vedotin for Use in Relapsed Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma. Nat. Biotechnol. 30(7) 2012: 631-637.
11. Hamblett KJ, et al. Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate. Clin. Cancer Res. 10(20) 2004: 7063-7070.
12. Junutula JR, et al. Site-Specific Conjugation of a Cytotoxic Drug to an Antibody Improves the Therapeutic Index. Nat. Biotechnol. 26(8) 2008: 928-932.
13. Junutula JR, et al. Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. Clin. Cancer Res. 16, 2010: 4769-4778.
14. Jeffrey SC, et al. A Potent Anti-CD70 Antibody-Drug Conjugate Combining a Dimeric Pyrrolobenzodiazepine Drug with Site-Specific Conjugation Technology. Bioconj. Chem. 24(7) 2013: 1256-1263.
15. Shen B, et al. Conjugation Site Modulates the In Vivo Stability and Therapeutic Activity of Antibody-Drug Conjugates. Nat. Biotechnol. 30(2) 2012: 184-191.
16. Axup JY, et al. Synthesis of Site-Specific Antibody-Drug Conjugates Using Unnatural Amino Acids. Proc. Natl. Acad. Sci. 109(40) 2012: 16101-16106.
17. Zimmerman ES, et al. Production of Site-Specific Antibody-Drug Conjugates Using Optimized Non-Natural Amino Acids in a Cell-Free Expression System. Bioconj. Chem. 25(2) 2014: 351-361.
18. Strop P, et al. Location Matters: Site of Conjugation Modulates Stability and Pharmacokinetics of Antibody Drug Conjugates. Chem. Biol. 20(2) 2013: 161-167.
19. Rabuka D, et al. Site-Specific Chemical Protein Conjugation Using Genetically Encoded Aldehyde Tags. Nat. Protocols 7(6) 2012: 1052-1067.
20. Tian F, et al. A General Approach to Site-Specific Antibody Drug Conjugates. Proc. Natl. Acad. Sci. 111(5) 2014: 1766-1771.
21. Jackson D, et al. In Vitro and In Vivo Evaluation of Cysteine and Site Specific Conjugated Herceptin Antibody-Drug Conjugates. PLOS One 14 January 2014: 1-14.
22. Hallam TJ. Concept to Clinic in 365 Days? 3rd World ADC Summit, San Francisco, CA, 24 October 2012; http://adc-summit.com/uploads/files/1972/Trevor-Hallam.pdf.
23. Strop P. Versatility of Microbial Transglutaminase. Bioconj. Chem. 25(5) 2014: 855-862.
24. Jeger S, et al. Site-Specific and Stoichiometric Modification of Antibodies By Bacterial Transglutaminase. Angew. Chem. Int. Ed. Eng. 49(51) 2010: 9995-9997.
25. Dennler P, et al. Transglutaminase-Based Chemo-Enzymatic Conjugation Approach Yields Homogeneous Antibody-Drug Conjugates. Bioconj. Chem. 25(3) 2014: 569-578.
26. Dorywalska MG, et al. WO 2012059882: Engineered Polypeptide Conjugates and Methods for Making There of Using Transglutaminase. Pfizer Inc., Rinat Neuroscience Corporation; www.google.com/patents/WO2012059882A3?cl=en.
27. Drake PM, et al. The Aldehyde Tag Coupled with HIPS Chemistry Enables the Production of ADCs Conjugated Site-Specifically to Different Antibody Regions with Distinct In Vivo Efficacy and PK Outcomes. Bioconj. Chem. 25(7) 2014: 1331-1341.